Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Azvudine in Renal Insufficiency
NCT07001436Phase 1Recruiting
- Sponsor
- Genuine Biotech
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azvudine in human immunodeficiency virus infection (HIV) and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Concentration at 48 hours, Area Under the Concentration-Time Curve from First Dose to Last Point at 48 hours and 1 more. Started May 2025; status: recruiting.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07001436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001436.